Ranolazine
- Generic Name
- Ranolazine
- Brand Names
- Aspruzyo Sprinkle, Ranexa, Ranexa (previously Latixa)
- Drug Type
- Small Molecule
- Chemical Formula
- C24H33N3O4
- CAS Number
- 95635-55-5
- Unique Ingredient Identifier
- A6IEZ5M406
- Background
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
- Indication
Ranolazine is indicated for the treatment of chronic angina. It can be used alone or in conjunction with nitrates, beta-blockers, angiotensin receptor blockers, anti-platelet drugs, calcium channel blockers, lipid-lowering drugs, and ACE inhibitors.
Ranolazine has also been used off-label for the treatment of certain arrhythmias, including ventricular tachycardia, however, this use is not strongly supported by scientific evidence. Ranolazine has also been studied for the treatment of acute coronary syndrome, microvascular coronary dysfunction, arrhythmia, and glycemic control, which are not yet approved indications.
- Associated Conditions
- Chronic Angina, Ventricular Arrhythmia
Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
- Conditions
- Diabetes, Type IDiabetes, Type IIAnginaCoronary Artery Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 47
- Registration Number
- NCT01754259
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
- First Posted Date
- 2012-11-16
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- Tel-Aviv Sourasky Medical Center
- Target Recruit Count
- 10
- Registration Number
- NCT01728025
- Locations
- 🇮🇱
Tel Aviv Medical Center, Tel Aviv, Israel
Ranolazine for the Treatment of Chest Pain in HCM Patients
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Duke University
- Target Recruit Count
- 14
- Registration Number
- NCT01721967
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
The Effects of Ranolazine on CPET Parameters in Ischemic Cardiomyopathy Patients (ERIC)
- First Posted Date
- 2012-10-12
- Last Posted Date
- 2020-02-18
- Lead Sponsor
- Cardiovascular Institute of the South Clinical Research Corporation
- Target Recruit Count
- 14
- Registration Number
- NCT01705509
- Locations
- 🇺🇸
Cardiovascular Institute of the South, Lafayette, Louisiana, United States
A Phase 1 Study to Assess the Effect of Severe Renal Impairment on the Pharmacokinetics, as Well as Safety/Tolerability, of Ranolazine
- First Posted Date
- 2012-08-30
- Last Posted Date
- 2012-12-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 4
- Registration Number
- NCT01675973
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 25
- Registration Number
- NCT01648205
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Randomized Double Blind Control Trial on Effects of Ranolazine on New Onset Atrial Fibrillation
- Conditions
- Atrial Fibrillation New OnsetVentricular TachycardiaMedical Care; Complications, Late Effect of ComplicationsHemorrhageProlonged QTc Interval
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-05-03
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- Northwell Health
- Target Recruit Count
- 54
- Registration Number
- NCT01590979
- Locations
- 🇺🇸
Staten Island University Hosptial, Staten Island, New York, United States
Evaluation of Exercise Treadmill Test (ETT) Indices in Participants With Cardiovascular Disease
- Conditions
- Atherosclerotic Coronary Vascular Disease
- Interventions
- First Posted Date
- 2012-03-23
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01562041
- Locations
- 🇺🇸
Novartis Investigative Site, New York, New York, United States
Safety of Amiodarone and Ranolazine Together in Patients With Angina
- Conditions
- Chronic Stable AnginaCoronary Artery DiseaseVentricular TachycardiaAtrial Fibrillation
- Interventions
- Drug: placebo
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2012-03-21
- Lead Sponsor
- Cardiovascular Consultants of Nevada
- Target Recruit Count
- 50
- Registration Number
- NCT01558830
- Locations
- 🇺🇸
Cardiovascular Consultants of Nevada, Las Vegas, Nevada, United States
A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Behavioral: DietBehavioral: Exercise
- First Posted Date
- 2012-03-15
- Last Posted Date
- 2014-09-23
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 442
- Registration Number
- NCT01555164
- Locations
- 🇺🇸
New Phase Research & Development, Knoxville, Tennessee, United States
🇺🇸National Research Institute, Los Angeles, California, United States
🇺🇸Baptist Diabetes Associates, Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.